TNF-α inhibitors and rheumatoid arthritis

Bibliography

• ELLIOT MJ, FELDMANN M, MAINI RN: TNF-a blockage in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action. Intern. J. Immunopharmac. (1995) 17(2):141–145.
   Google Scholar
• TALLEY JJ: Selective inhibitors of cyclooxygenase-2. Exp. Opin. Ther. Patents (1997) 7(0:55–62.
   Web of Science ®Google Scholar
• •This is a good review of types of compounds being investi-gated in the COX area.
   Google Scholar
• BONDESON J: The mechanism of action of disease-modifying antirheumatic drugs: a review with empha-sis on macrophage signal transduction and the induc-tion of proinflammatory cytokines. Gen. Pharmac. (1997) 29(2):127–150.
   PubMedGoogle Scholar
• SEKUT L, CONNOLLY KM: Pathophysiology and regula-tion of TNF-a in inflammation. Drug News Perspect. (1996) 9(5): 261–269.
   Web of Science ®Google Scholar
• MANNEL DN, MOORE RN, MERGENHAGEN SE: Macro-phages as a source of tumoricidal activity (tumor-necrotizing factor). Infect. Immun. (1980) 30:523–530.
   PubMed Web of Science ®Google Scholar
• SATOMI N, HARANAKA K, KUNII O. Research on the pro-duction site of tumor necrosis factor (TNF). Jpn. J. Exp. Med. (1981) 51:317–322.
   Google Scholar
• TRACEY K: Tumor necrosis factor (cachectin) in the bi-ology of septic shock syndrome. Circ. Shock (1991) 35:123–28.
   PubMedGoogle Scholar
• TRACEY K, WET H, MANOGUE K et al.: Cachectin/tumornecrosis factor induces cachexia, anemia and inflam-mation. J. Exp. Med. (1988) 167:1211–27.
   PubMed Web of Science ®Google Scholar
• MAINI R, ELLIOTT M, BRENNAN F, FELDMANN M: Benefi-cial effects of tumour necrosis factor-alpha (TNF-) blockade in rheumatoid arthritis. Clin. Exp. Im-munol (1995) 101(2):207–212.
   PubMed Web of Science ®Google Scholar
• SYMINGTON F, PEPE M, DELIGANIS A: Serum tumor ne- factor alpha associated with acute graft-ver-sus-host disease in humans. Transplantation (1990) 50:518–21.
   PubMed Web of Science ®Google Scholar
• STEPHENS K, ISHIZAKA A, LARRICK J, RAFFIN T: Tumor necrosis factor causes increased pulmonary perme-ability and edema. Am. Rev. Resp. Dis. (1988) 137:1364–70.
   PubMed Web of Science ®Google Scholar
• FOLKS T, CLOUSE K, JUSTEMENT J et al.: Tumor necrosis factor alpha induces expression of human immunode-ficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. USA (1989) 86:2365–68.
   PubMed Web of Science ®Google Scholar
• EIGLER A, BHANU S, HATMANN G, ENDRES S: Taming TNF: strategies to restrain this proinflammatory cyto-kine. Immunol. Today (1997) 18(10): 487–492.
   Google Scholar
• MARRIOT JB, WESTBY M, DALGLEISH AG: Therapeutic potential of TNF-a inhibitors old and new. Drug Disc. Today (1997) 2(7):273–282.
   Google Scholar
• •An introductory paper to the area of TNF inhibition as a therapeutic target for a variety of diseases.
   Google Scholar
• LEE J, PRABHAKAR U, GRISWOLD D et al.: Low-molecular-weight TNF biosynthesis inhibitors: strate-gies and prospectives. Circ. Shock (1995) 44:97–103.
   Google Scholar
• FELDMAN M, ELLIOT MJ,WOODY JN, MAINI RN: Anti-tumor necrosis factor-a therapy of rheumatoid arthri-tis. Adv. Immunol. (1997) 64:283–350.
   Google Scholar
• ••This in-depth review covers the area of TNF inhibition andRA and includes some clinical studies.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Eng. J. Med. (1997) 337(3):141–147.
   PubMed Web of Science ®Google Scholar
• Promising arthritis treatments emerge. Scrip (1996) 2176:21.
   Google Scholar
• LOMBARO LJ: Phosphodiesterase-IV inhibitors: novel therapeutics for the treatment of inflammatory dis-eases. Curr. Pharm. Design (1995) 1:255–268.
   Google Scholar
• TROPHY TJ, Phosphodiesterase inhibitors. In: Asthma. Leff AR, Woolcock AJ (Eds.), Lippincott-Raven Publishers, Philadelphia (1997):1755–1773.
   Google Scholar
• •Discusses the PDE families with particular emphasis on PDE4.
   Google Scholar
• SCHWABE U, MIYAKE M, OHGA Y, DALY J: 4- (3-Cyclopentoxy-4-methoxy)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',4'-monopho-sphate phosphodiesterase in homogenates and tissue slices from rat brain. Mol. Pharmacol. (1976) 12:900–910.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REIFSNYDER, DH: Primary sequence of cy-clic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci. (1990) 11:150–155.
   PubMed Web of Science ®Google Scholar
• MULLER GW: Unpublished results from Celgene Corpora-tion.
   Google Scholar
• MARIVET MC, BOURGUIGNON J-J, LUGNIER C et al: Inhi-bition of cyclic adenosine-3 ',5'-monophosphate from vascular smooth muscle by rolipram analogues. J. Med. Chem. (1989) 32:1450–1457.
   PubMed Web of Science ®Google Scholar
• SACCOMANO NA, VINICK FJ, KOE K et al.:Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy-4-methoxypheny1]-2-imidazolidinones. J. Med. Chem. (1991) 34:291–298.
   Google Scholar
• STAFFORD JA, FELDMAN PL, MARRON BE et al.: Structure-activity relationships involving the catechol subunit of rolipram. Bioorg. Med. Chem. Lett. (1994) 4(15):1855–1860.
   Google Scholar
• CAVALLA D, FRITH R: Phosphodiesterase IV inhibitors:structural diversity and therapeutic potential in asthma. Curr. Med. Chem. (1995) 2: 561–572.
   Web of Science ®Google Scholar
• STIRLING D: Mechanism of action of thalidomide andanalogues. Cambridge Symposia. Santa Fe (April 1997).
   Google Scholar
• MULLER GW, CORRAL LG, SHIRE MG et al.: Structuralmodifications of thalidomide produce analogues with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem. (1996) 39:3238–3240.
   PubMed Web of Science ®Google Scholar
• ASHTON M, COOK DC, FENTON G eta].: Selective TypeIV phosphodiesterase inhibitors as anti-asthmatic agents. The synthesis and biological activities of 3-cyclopentoxy-4-methoxybenzamides and analogues. J. Med. Chem. (1994) 37:1696–1703.
   Google Scholar
• KLEINMAN EF, CAMPBELL E, GIORDANO LA eta].: Strik-ing effect of hydroxamic acid substitution on the phos-phodiesterase type 4 (PDE4) and TNF-a inhibitory activity of two series of rolipram analogues: implica-tions for a new active site model of PDE4. J. Med. Chem. (1998) 41:266–270.
   Google Scholar
• •PDE and TNF data are presented for a number of com-pounds in addition to synthetic processes.
   Google Scholar
• ZABEL P, SCHADE FU, SCHLAAK M: Inhibition of en-dogenous TNF formation by pentoxifylline. Immuno-biology (1993) 187:447–463.
   PubMed Web of Science ®Google Scholar
• ANAYA J-M, ESPINOZA LR: Phosphodiesterase inhibitorpentoxifylline: an antiinflammatory/immunomodu-latory drug potentially useful in some rheumatic dis-eases. J. Rheumatol. (1995) 22:595–599.
   Google Scholar
• DENT G, RABE KF: Effects of theophylline and non-selective xanthine derivatives on PDE isoenzymes and cellular function. In: Phosphodiesterase Inhibitors. Schundt C, Dent G, Rabe KF (Eds.), Academic Press, San Di-ego (1996):41–64.
   Google Scholar
• CHIKANZA IC, FERNANDES L: The current status and fu-ture prospects for biological targeted therapies for rheumatoid arthritis. Exp. Opin. Invest. Drugs (1996) 5 (7):819–828.
   Google Scholar
• MOHLER KM, SLEATH PR, FITZNER JN et al.: Protectionagainst a lethal dose of endotoxin by an inhibitor of tu-mour necrosis factor processing. Nature (1994) 370:218–220.
   PubMed Web of Science ®Google Scholar
• MCGEEHAN GM, BECHERER JD, BAST RC et al.: Regula- of tumour necrosis factor-a by a metalloprote-inase inhibitor. Nature (1994) 370:558–561.
   PubMed Web of Science ®Google Scholar
• •The beginning of the identification of a relationship be-tween MMPs and TNF processing.
   Google Scholar
• GEARING AJH, BECKETT P, CHRISTODOULOU M et al.: of tumour necrosis factor-a precursor by metalloproteinases. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• •The beginning of the identification of a relationship be-tween MMPs and TNF processing.
   Google Scholar
• BLACK RA, RAUCH CT, KOZOSKY CJ: A metalloprote- disintegrin that releases tumour-necrosis fac - tor-a from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• •The beginning of the identification of a relationship be-tween MMPs and TNF processing.
   Google Scholar
• MOSS ML, JIN S-LC, MILLA ME et al.: Cloning of a disin-tegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature (1997) 385:733–736.
   PubMed Web of Science ®Google Scholar
• ••Cloning of the MMP believed to be TACE.
   Google Scholar
• BIRKEDAL-HANSEN H, MOORES WGI, BODDEN MK et al: Matrix metalloproteinases: a review. Grit. Rev. Oral Biol. Med. (1993) 4:197–250.
   PubMedGoogle Scholar
• ••Cloning of the MMP believed to be TACE.
   Google Scholar
• DIMARTION M, WOLFF C, HIGH W et al.: Anti-arthritic activity of hydroxamic acid-based pseudopeptide in-hibitors of matrix metalloproteinases and TNF-a proc-essing. Inflamm. Res. (1997) 46:211–215.
   Google Scholar
• CONWAY JG, WAKEFIELD JA, BROWN RH et al.: Inhibi-tion of cartilage and bone destruction in adjuvant ar-thritis in the rat by a matrix metalloproteinase inhibitor. J. Exp. Med. (1995) 182: 449–457.
   PubMed Web of Science ®Google Scholar
• DHANARAJ V, YE Q-Z, JOHNSON LL et al: X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure (1996) 4(4):375–385.
   Google Scholar
• BAXTER AD, BIRD J, BHOGAL R et al: A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders. Bioorg. Med. Chem. Lett. (1997) 7(7)897–902.
   Google Scholar
• BAXTER AD, BHOGAL R, BIRD JB et al: Mercaptoacyl ma-trix metalloproteinase inhibitors: the effects of substi-tution at the mercaptoacyl moiety. Biorg. Med. Chem. Lett. (1997) 7(20:2765–2770.
   Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY et al: Thalidomide se-lectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ-RODRIGUEZ O: Thalidomide: a promisingtreatment for rheumatoid arthritis. Arthr. Rheum. (1984) 27(101118–1121.
   Google Scholar